XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%.
Financial reports indicate that XOMA achieved a revenue of $11.09 million, net profit of $15.99 million, and earnings per share of $0.88. The gross profit stood at $11.08 million, with a price-to-earnings ratio of -11.85.
Within the industry, 67% of analysts from three rating agencies recommend buying the stock, while 33% suggest holding. Notably, no agency recommended selling XOMA shares.
The biotechnology sector, where XOMA operates, experienced an overall decline of 1.76%. However, stocks such as Elevai Labs, Inc., Transcode Therapeutics, Inc., and Theriva Biologics, Inc. recorded significant gains. Theriva Biologics, Inc., Aditxt, Inc., and Elevai Labs, Inc. were highly active with turnover rates of 5378.69%, 1603.03%, and 946.36%, respectively. Stocks with notable price fluctuations included Psyence Biomedical Ltd, Elevai Labs, Inc., and Seastar Medical Holding Corp.
XOMA is instrumental in assisting biotech companies to fulfill their goals of improving human health by acquiring potential future economic benefits associated with pre-commercialized therapeutic candidates licensed to pharmaceutical or biotech firms. XOMA provides non-dilutive, non-recourse funding to sellers, which can be utilized for advancing their internal drug candidates or general corporate purposes.
